Emicizumab Prophylaxis in Hemophilia A with Inhibitors | Zendy

Johannes Oldenburg | Zendy; Johnny Mahlangu | Zendy; Benjamin Kim | Zendy; Christophe Schmitt | Zendy; Michael U. Callaghan | Zendy; Guy Young | Zendy; Elena Santagostino | Zendy; Rebecca KruseJarres | Zendy; Claude Négrier | Zendy; Craig M. Kessler | Zendy; Nancy Valente | Zendy; Elina Asikanius | Zendy; Gallia G. Levy | Zendy; Jerzy Windyga | Zendy; Midori Shima | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Author(s) -

Johannes Oldenburg,

Johnny Mahlangu,

Benjamin Kim,

Christophe Schmitt,

Michael U. Callaghan,

Guy Young,

Elena Santagostino,

Rebecca KruseJarres,

Claude Négrier,

Craig M. Kessler,

Nancy Valente,

Elina Asikanius,

Gallia G. Levy,

Jerzy Windyga,

Midori Shima

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1703068

Subject(s) - medicine , factor ix , clinical trial , pediatrics

Emicizumab (ACE910) bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in persons with hemophilia A. This phase 3, multicenter trial assessed once-weekly subcutaneous emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research